^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    rezetamig (JNJ-8780)

    i
    Other names: JNJ-8780, JNJ-75348780
    Associations
    News

    Trials

    Company:
    J&J
    Drug class:
    CD3 agonist, CD22 inhibitor
    Related drugs:
    Associations
    News

    Trials

    Apply
    A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) (NCT04540796)
    Phase 1
    Janssen Research & Development, LLC
    Active, not recruiting
    Last update posted :
    02/03/2025
    Initiation :
    11/20/2020
    Primary completion :
    04/04/2025
    Completion :
    05/31/2025
    BCL2
    |
    rezetamig (JNJ-8780)